SB1454 EngrossedLRB098 09389 RPM 39530 b

1    AN ACT concerning health.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Wholesale Drug Distribution Licensing Act is
5amended by changing Section 40 as follows:
 
6    (225 ILCS 120/40)  (from Ch. 111, par. 8301-40)
7    (Section scheduled to be repealed on January 1, 2023)
8    Sec. 40. Rules and regulations. The Department shall make
9any rules and regulations, not inconsistent with law, as may be
10necessary to carry out the purposes and enforce the provisions
11of this Act. Rules and regulations that incorporate and set
12detailed standards for meeting each of the license
13prerequisites set forth in Section 25 of this Act shall be
14adopted no later than September 14, 1992. All rules and
15regulations promulgated under this Section shall conform to
16wholesale drug distributor licensing guidelines formally
17adopted by the FDA at 21 C.F.R. Part 205. In case of conflict
18between any rule or regulation adopted by the Department and
19any FDA wholesale drug distributor guideline, the FDA guideline
20shall control.
21    Notwithstanding any other provision of law, a distributor
22licensed and regulated by the Department of Financial and
23Professional Regulation, and registered and regulated by the

 

 

SB1454 Engrossed- 2 -LRB098 09389 RPM 39530 b

1United States Drug Enforcement Administration, shall be exempt
2from the storage, reporting, ordering, record keeping, and
3physical security control requirements for Schedule II
4controlled substances with regard to any material, compound,
5mixture, or preparation containing Hydrocodone. These
6controlled substances shall be subject to the same requirements
7as those imposed for Schedule III controlled substances.
8(Source: P.A. 87-594.)
 
9    Section 10. The Illinois Controlled Substances Act is
10amended by changing Sections 102, 316, 319, and 320 and by
11adding Sections 208.5 and 317.5 as follows:
 
12    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
13    Sec. 102. Definitions. As used in this Act, unless the
14context otherwise requires:
15    (a) "Addict" means any person who habitually uses any drug,
16chemical, substance or dangerous drug other than alcohol so as
17to endanger the public morals, health, safety or welfare or who
18is so far addicted to the use of a dangerous drug or controlled
19substance other than alcohol as to have lost the power of self
20control with reference to his or her addiction.
21    (b) "Administer" means the direct application of a
22controlled substance, whether by injection, inhalation,
23ingestion, or any other means, to the body of a patient,
24research subject, or animal (as defined by the Humane

 

 

SB1454 Engrossed- 3 -LRB098 09389 RPM 39530 b

1Euthanasia in Animal Shelters Act) by:
2        (1) a practitioner (or, in his or her presence, by his
3    or her authorized agent),
4        (2) the patient or research subject pursuant to an
5    order, or
6        (3) a euthanasia technician as defined by the Humane
7    Euthanasia in Animal Shelters Act.
8    (c) "Agent" means an authorized person who acts on behalf
9of or at the direction of a manufacturer, distributor,
10dispenser, prescriber, or practitioner. It does not include a
11common or contract carrier, public warehouseman or employee of
12the carrier or warehouseman.
13    (c-1) "Anabolic Steroids" means any drug or hormonal
14substance, chemically and pharmacologically related to
15testosterone (other than estrogens, progestins,
16corticosteroids, and dehydroepiandrosterone), and includes:
17    (i) 3[beta],17-dihydroxy-5a-androstane, 
18    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
19    (iii) 5[alpha]-androstan-3,17-dione, 
20    (iv) 1-androstenediol (3[beta], 
21        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
22    (v) 1-androstenediol (3[alpha], 
23        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
24    (vi) 4-androstenediol  
25        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
26    (vii) 5-androstenediol  

 

 

SB1454 Engrossed- 4 -LRB098 09389 RPM 39530 b

1        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
2    (viii) 1-androstenedione  
3        ([5alpha]-androst-1-en-3,17-dione), 
4    (ix) 4-androstenedione  
5        (androst-4-en-3,17-dione), 
6    (x) 5-androstenedione  
7        (androst-5-en-3,17-dione), 
8    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
9        hydroxyandrost-4-en-3-one), 
10    (xii) boldenone (17[beta]-hydroxyandrost- 
11        1,4,-diene-3-one), 
12    (xiii) boldione (androsta-1,4- 
13        diene-3,17-dione), 
14    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
15        [beta]-hydroxyandrost-4-en-3-one), 
16    (xv) clostebol (4-chloro-17[beta]- 
17        hydroxyandrost-4-en-3-one), 
18    (xvi) dehydrochloromethyltestosterone (4-chloro- 
19        17[beta]-hydroxy-17[alpha]-methyl- 
20        androst-1,4-dien-3-one), 
21    (xvii) desoxymethyltestosterone 
22    (17[alpha]-methyl-5[alpha] 
23        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
24    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
25        '1-testosterone') (17[beta]-hydroxy- 
26        5[alpha]-androst-1-en-3-one), 

 

 

SB1454 Engrossed- 5 -LRB098 09389 RPM 39530 b

1    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
2        androstan-3-one), 
3    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
4        5[alpha]-androstan-3-one), 
5    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
6        hydroxyestr-4-ene), 
7    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
8        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
9    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
10        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
11    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
12        hydroxyandrostano[2,3-c]-furazan), 
13    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) 
14    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
15        androst-4-en-3-one), 
16    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
17        dihydroxy-estr-4-en-3-one), 
18    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
19        hydroxy-5-androstan-3-one), 
20    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
21        [5a]-androstan-3-one), 
22    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
23        hydroxyandrost-1,4-dien-3-one), 
24    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
25        dihydroxyandrost-5-ene), 
26    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 

 

 

SB1454 Engrossed- 6 -LRB098 09389 RPM 39530 b

1        5[alpha]-androst-1-en-3-one), 
2    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
3        dihydroxy-5a-androstane), 
4    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
5        -5a-androstane), 
6    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
7        dihydroxyandrost-4-ene), 
8    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
9        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
10    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
11        hydroxyestra-4,9(10)-dien-3-one), 
12    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
13        hydroxyestra-4,9-11-trien-3-one), 
14    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
15        hydroxyandrost-4-en-3-one), 
16    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
17        hydroxyestr-4-en-3-one), 
18    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
19        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
20        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
21        1-testosterone'), 
22    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
23    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
24        dihydroxyestr-4-ene), 
25    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
26        dihydroxyestr-4-ene), 

 

 

SB1454 Engrossed- 7 -LRB098 09389 RPM 39530 b

1    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
2        dihydroxyestr-5-ene), 
3    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
4        dihydroxyestr-5-ene), 
5    (xlvii) 19-nor-4,9(10)-androstadienedione  
6        (estra-4,9(10)-diene-3,17-dione), 
7    (xlviii) 19-nor-4-androstenedione (estr-4- 
8        en-3,17-dione), 
9    (xlix) 19-nor-5-androstenedione (estr-5- 
10        en-3,17-dione), 
11    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
12        hydroxygon-4-en-3-one), 
13    (li) norclostebol (4-chloro-17[beta]- 
14        hydroxyestr-4-en-3-one), 
15    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
16        hydroxyestr-4-en-3-one), 
17    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
18        hydroxyestr-4-en-3-one), 
19    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
20        2-oxa-5[alpha]-androstan-3-one), 
21    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
22        dihydroxyandrost-4-en-3-one), 
23    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
24        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
25    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
26        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 

 

 

SB1454 Engrossed- 8 -LRB098 09389 RPM 39530 b

1    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
2        (5[alpha]-androst-1-en-3-one), 
3    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
4        secoandrosta-1,4-dien-17-oic 
5        acid lactone), 
6    (lx) testosterone (17[beta]-hydroxyandrost- 
7        4-en-3-one), 
8    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
9        diethyl-17[beta]-hydroxygon- 
10        4,9,11-trien-3-one), 
11    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
12        11-trien-3-one). 
13    Any person who is otherwise lawfully in possession of an
14anabolic steroid, or who otherwise lawfully manufactures,
15distributes, dispenses, delivers, or possesses with intent to
16deliver an anabolic steroid, which anabolic steroid is
17expressly intended for and lawfully allowed to be administered
18through implants to livestock or other nonhuman species, and
19which is approved by the Secretary of Health and Human Services
20for such administration, and which the person intends to
21administer or have administered through such implants, shall
22not be considered to be in unauthorized possession or to
23unlawfully manufacture, distribute, dispense, deliver, or
24possess with intent to deliver such anabolic steroid for
25purposes of this Act.
26    (d) "Administration" means the Drug Enforcement

 

 

SB1454 Engrossed- 9 -LRB098 09389 RPM 39530 b

1Administration, United States Department of Justice, or its
2successor agency.
3    (d-5) "Clinical Director, Prescription Monitoring Program"
4means a Department of Human Services administrative employee
5licensed to either prescribe or dispense controlled substances
6who shall run the clinical aspects of the Department of Human
7Services Prescription Monitoring Program and its Prescription
8Information Library.
9    (d-10) "Compounding" means the preparation and mixing of
10components, excluding flavorings, (1) as the result of a
11prescriber's prescription drug order or initiative based on the
12prescriber-patient-pharmacist relationship in the course of
13professional practice or (2) for the purpose of, or incident
14to, research, teaching, or chemical analysis and not for sale
15or dispensing. "Compounding" includes the preparation of drugs
16or devices in anticipation of receiving prescription drug
17orders based on routine, regularly observed dispensing
18patterns. Commercially available products may be compounded
19for dispensing to individual patients only if both of the
20following conditions are met: (i) the commercial product is not
21reasonably available from normal distribution channels in a
22timely manner to meet the patient's needs and (ii) the
23prescribing practitioner has requested that the drug be
24compounded.
25    (e) "Control" means to add a drug or other substance, or
26immediate precursor, to a Schedule whether by transfer from

 

 

SB1454 Engrossed- 10 -LRB098 09389 RPM 39530 b

1another Schedule or otherwise.
2    (f) "Controlled Substance" means (i) a drug, substance, or
3immediate precursor in the Schedules of Article II of this Act
4or (ii) a drug or other substance, or immediate precursor,
5designated as a controlled substance by the Department through
6administrative rule. The term does not include distilled
7spirits, wine, malt beverages, or tobacco, as those terms are
8defined or used in the Liquor Control Act and the Tobacco
9Products Tax Act.
10    (f-5) "Controlled substance analog" means a substance:
11        (1) the chemical structure of which is substantially
12    similar to the chemical structure of a controlled substance
13    in Schedule I or II;
14        (2) which has a stimulant, depressant, or
15    hallucinogenic effect on the central nervous system that is
16    substantially similar to or greater than the stimulant,
17    depressant, or hallucinogenic effect on the central
18    nervous system of a controlled substance in Schedule I or
19    II; or
20        (3) with respect to a particular person, which such
21    person represents or intends to have a stimulant,
22    depressant, or hallucinogenic effect on the central
23    nervous system that is substantially similar to or greater
24    than the stimulant, depressant, or hallucinogenic effect
25    on the central nervous system of a controlled substance in
26    Schedule I or II.

 

 

SB1454 Engrossed- 11 -LRB098 09389 RPM 39530 b

1    (g) "Counterfeit substance" means a controlled substance,
2which, or the container or labeling of which, without
3authorization bears the trademark, trade name, or other
4identifying mark, imprint, number or device, or any likeness
5thereof, of a manufacturer, distributor, or dispenser other
6than the person who in fact manufactured, distributed, or
7dispensed the substance.
8    (h) "Deliver" or "delivery" means the actual, constructive
9or attempted transfer of possession of a controlled substance,
10with or without consideration, whether or not there is an
11agency relationship.
12    (i) "Department" means the Illinois Department of Human
13Services (as successor to the Department of Alcoholism and
14Substance Abuse) or its successor agency.
15    (j) (Blank).
16    (k) "Department of Corrections" means the Department of
17Corrections of the State of Illinois or its successor agency.
18    (l) "Department of Financial and Professional Regulation"
19means the Department of Financial and Professional Regulation
20of the State of Illinois or its successor agency.
21    (m) "Depressant" means any drug that (i) causes an overall
22depression of central nervous system functions, (ii) causes
23impaired consciousness and awareness, and (iii) can be
24habit-forming or lead to a substance abuse problem, including
25but not limited to alcohol, cannabis and its active principles
26and their analogs, benzodiazepines and their analogs,

 

 

SB1454 Engrossed- 12 -LRB098 09389 RPM 39530 b

1barbiturates and their analogs, opioids (natural and
2synthetic) and their analogs, and chloral hydrate and similar
3sedative hypnotics.
4    (n) (Blank).
5    (o) "Director" means the Director of the Illinois State
6Police or his or her designated agents.
7    (p) "Dispense" means to deliver a controlled substance to
8an ultimate user or research subject by or pursuant to the
9lawful order of a prescriber, including the prescribing,
10administering, packaging, labeling, or compounding necessary
11to prepare the substance for that delivery.
12    (q) "Dispenser" means a practitioner who dispenses.
13    (r) "Distribute" means to deliver, other than by
14administering or dispensing, a controlled substance.
15    (s) "Distributor" means a person who distributes.
16    (t) "Drug" means (1) substances recognized as drugs in the
17official United States Pharmacopoeia, Official Homeopathic
18Pharmacopoeia of the United States, or official National
19Formulary, or any supplement to any of them; (2) substances
20intended for use in diagnosis, cure, mitigation, treatment, or
21prevention of disease in man or animals; (3) substances (other
22than food) intended to affect the structure of any function of
23the body of man or animals and (4) substances intended for use
24as a component of any article specified in clause (1), (2), or
25(3) of this subsection. It does not include devices or their
26components, parts, or accessories.

 

 

SB1454 Engrossed- 13 -LRB098 09389 RPM 39530 b

1    (t-3) "Electronic health record" or "EHR" means a
2systematic collection of electronic health information about
3individual patients. The EHR is a digital format that is
4capable of being shared across different health care settings.
5    (t-5) "Euthanasia agency" means an entity certified by the
6Department of Financial and Professional Regulation for the
7purpose of animal euthanasia that holds an animal control
8facility license or animal shelter license under the Animal
9Welfare Act. A euthanasia agency is authorized to purchase,
10store, possess, and utilize Schedule II nonnarcotic and
11Schedule III nonnarcotic drugs for the sole purpose of animal
12euthanasia.
13    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
14substances (nonnarcotic controlled substances) that are used
15by a euthanasia agency for the purpose of animal euthanasia.
16    (u) "Good faith" means the prescribing or dispensing of a
17controlled substance by a practitioner in the regular course of
18professional treatment to or for any person who is under his or
19her treatment for a pathology or condition other than that
20individual's physical or psychological dependence upon or
21addiction to a controlled substance, except as provided herein:
22and application of the term to a pharmacist shall mean the
23dispensing of a controlled substance pursuant to the
24prescriber's order which in the professional judgment of the
25pharmacist is lawful. The pharmacist shall be guided by
26accepted professional standards including, but not limited to

 

 

SB1454 Engrossed- 14 -LRB098 09389 RPM 39530 b

1the following, in making the judgment:
2        (1) lack of consistency of prescriber-patient
3    relationship,
4        (2) frequency of prescriptions for same drug by one
5    prescriber for large numbers of patients,
6        (3) quantities beyond those normally prescribed,
7        (4) unusual dosages (recognizing that there may be
8    clinical circumstances where more or less than the usual
9    dose may be used legitimately),
10        (5) unusual geographic distances between patient,
11    pharmacist and prescriber,
12        (6) consistent prescribing of habit-forming drugs.
13    (u-0.5) "Hallucinogen" means a drug that causes markedly
14altered sensory perception leading to hallucinations of any
15type.
16    (u-1) "Home infusion services" means services provided by a
17pharmacy in compounding solutions for direct administration to
18a patient in a private residence, long-term care facility, or
19hospice setting by means of parenteral, intravenous,
20intramuscular, subcutaneous, or intraspinal infusion.
21    (u-5) "Illinois State Police" means the State Police of the
22State of Illinois, or its successor agency.
23    (v) "Immediate precursor" means a substance:
24        (1) which the Department has found to be and by rule
25    designated as being a principal compound used, or produced
26    primarily for use, in the manufacture of a controlled

 

 

SB1454 Engrossed- 15 -LRB098 09389 RPM 39530 b

1    substance;
2        (2) which is an immediate chemical intermediary used or
3    likely to be used in the manufacture of such controlled
4    substance; and
5        (3) the control of which is necessary to prevent,
6    curtail or limit the manufacture of such controlled
7    substance.
8    (w) "Instructional activities" means the acts of teaching,
9educating or instructing by practitioners using controlled
10substances within educational facilities approved by the State
11Board of Education or its successor agency.
12    (x) "Local authorities" means a duly organized State,
13County or Municipal peace unit or police force.
14    (y) "Look-alike substance" means a substance, other than a
15controlled substance which (1) by overall dosage unit
16appearance, including shape, color, size, markings or lack
17thereof, taste, consistency, or any other identifying physical
18characteristic of the substance, would lead a reasonable person
19to believe that the substance is a controlled substance, or (2)
20is expressly or impliedly represented to be a controlled
21substance or is distributed under circumstances which would
22lead a reasonable person to believe that the substance is a
23controlled substance. For the purpose of determining whether
24the representations made or the circumstances of the
25distribution would lead a reasonable person to believe the
26substance to be a controlled substance under this clause (2) of

 

 

SB1454 Engrossed- 16 -LRB098 09389 RPM 39530 b

1subsection (y), the court or other authority may consider the
2following factors in addition to any other factor that may be
3relevant:
4        (a) statements made by the owner or person in control
5    of the substance concerning its nature, use or effect;
6        (b) statements made to the buyer or recipient that the
7    substance may be resold for profit;
8        (c) whether the substance is packaged in a manner
9    normally used for the illegal distribution of controlled
10    substances;
11        (d) whether the distribution or attempted distribution
12    included an exchange of or demand for money or other
13    property as consideration, and whether the amount of the
14    consideration was substantially greater than the
15    reasonable retail market value of the substance.
16    Clause (1) of this subsection (y) shall not apply to a
17noncontrolled substance in its finished dosage form that was
18initially introduced into commerce prior to the initial
19introduction into commerce of a controlled substance in its
20finished dosage form which it may substantially resemble.
21    Nothing in this subsection (y) prohibits the dispensing or
22distributing of noncontrolled substances by persons authorized
23to dispense and distribute controlled substances under this
24Act, provided that such action would be deemed to be carried
25out in good faith under subsection (u) if the substances
26involved were controlled substances.

 

 

SB1454 Engrossed- 17 -LRB098 09389 RPM 39530 b

1    Nothing in this subsection (y) or in this Act prohibits the
2manufacture, preparation, propagation, compounding,
3processing, packaging, advertising or distribution of a drug or
4drugs by any person registered pursuant to Section 510 of the
5Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
6    (y-1) "Mail-order pharmacy" means a pharmacy that is
7located in a state of the United States that delivers,
8dispenses or distributes, through the United States Postal
9Service or other common carrier, to Illinois residents, any
10substance which requires a prescription.
11    (z) "Manufacture" means the production, preparation,
12propagation, compounding, conversion or processing of a
13controlled substance other than methamphetamine, either
14directly or indirectly, by extraction from substances of
15natural origin, or independently by means of chemical
16synthesis, or by a combination of extraction and chemical
17synthesis, and includes any packaging or repackaging of the
18substance or labeling of its container, except that this term
19does not include:
20        (1) by an ultimate user, the preparation or compounding
21    of a controlled substance for his or her own use; or
22        (2) by a practitioner, or his or her authorized agent
23    under his or her supervision, the preparation,
24    compounding, packaging, or labeling of a controlled
25    substance:
26            (a) as an incident to his or her administering or

 

 

SB1454 Engrossed- 18 -LRB098 09389 RPM 39530 b

1        dispensing of a controlled substance in the course of
2        his or her professional practice; or
3            (b) as an incident to lawful research, teaching or
4        chemical analysis and not for sale.
5    (z-1) (Blank).
6    (z-5) "Medication shopping" means the conduct prohibited
7under subsection (a) of Section 314.5 of this Act.
8    (z-10) "Mid-level practitioner" means (i) a physician
9assistant who has been delegated authority to prescribe through
10a written delegation of authority by a physician licensed to
11practice medicine in all of its branches, in accordance with
12Section 7.5 of the Physician Assistant Practice Act of 1987,
13(ii) an advanced practice nurse who has been delegated
14authority to prescribe through a written delegation of
15authority by a physician licensed to practice medicine in all
16of its branches or by a podiatrist, in accordance with Section
1765-40 of the Nurse Practice Act, or (iii) an animal euthanasia
18agency.
19    (aa) "Narcotic drug" means any of the following, whether
20produced directly or indirectly by extraction from substances
21of vegetable origin, or independently by means of chemical
22synthesis, or by a combination of extraction and chemical
23synthesis:
24        (1) opium, opiates, derivatives of opium and opiates,
25    including their isomers, esters, ethers, salts, and salts
26    of isomers, esters, and ethers, whenever the existence of

 

 

SB1454 Engrossed- 19 -LRB098 09389 RPM 39530 b

1    such isomers, esters, ethers, and salts is possible within
2    the specific chemical designation; however the term
3    "narcotic drug" does not include the isoquinoline
4    alkaloids of opium;
5        (2) (blank);
6        (3) opium poppy and poppy straw;
7        (4) coca leaves, except coca leaves and extracts of
8    coca leaves from which substantially all of the cocaine and
9    ecgonine, and their isomers, derivatives and salts, have
10    been removed;
11        (5) cocaine, its salts, optical and geometric isomers,
12    and salts of isomers;
13        (6) ecgonine, its derivatives, their salts, isomers,
14    and salts of isomers;
15        (7) any compound, mixture, or preparation which
16    contains any quantity of any of the substances referred to
17    in subparagraphs (1) through (6).
18    (bb) "Nurse" means a registered nurse licensed under the
19Nurse Practice Act.
20    (cc) (Blank).
21    (dd) "Opiate" means any substance having an addiction
22forming or addiction sustaining liability similar to morphine
23or being capable of conversion into a drug having addiction
24forming or addiction sustaining liability.
25    (ee) "Opium poppy" means the plant of the species Papaver
26somniferum L., except its seeds.

 

 

SB1454 Engrossed- 20 -LRB098 09389 RPM 39530 b

1    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
2solution or other liquid form of medication intended for
3administration by mouth, but the term does not include a form
4of medication intended for buccal, sublingual, or transmucosal
5administration.
6    (ff) "Parole and Pardon Board" means the Parole and Pardon
7Board of the State of Illinois or its successor agency.
8    (gg) "Person" means any individual, corporation,
9mail-order pharmacy, government or governmental subdivision or
10agency, business trust, estate, trust, partnership or
11association, or any other entity.
12    (hh) "Pharmacist" means any person who holds a license or
13certificate of registration as a registered pharmacist, a local
14registered pharmacist or a registered assistant pharmacist
15under the Pharmacy Practice Act.
16    (ii) "Pharmacy" means any store, ship or other place in
17which pharmacy is authorized to be practiced under the Pharmacy
18Practice Act.
19    (ii-5) "Pharmacy shopping" means the conduct prohibited
20under subsection (b) of Section 314.5 of this Act.
21    (ii-10) "Physician" (except when the context otherwise
22requires) means a person licensed to practice medicine in all
23of its branches.
24    (jj) "Poppy straw" means all parts, except the seeds, of
25the opium poppy, after mowing.
26    (kk) "Practitioner" means a physician licensed to practice

 

 

SB1454 Engrossed- 21 -LRB098 09389 RPM 39530 b

1medicine in all its branches, dentist, optometrist,
2podiatrist, veterinarian, scientific investigator, pharmacist,
3physician assistant, advanced practice nurse, licensed
4practical nurse, registered nurse, hospital, laboratory, or
5pharmacy, or other person licensed, registered, or otherwise
6lawfully permitted by the United States or this State to
7distribute, dispense, conduct research with respect to,
8administer or use in teaching or chemical analysis, a
9controlled substance in the course of professional practice or
10research.
11    (ll) "Pre-printed prescription" means a written
12prescription upon which the designated drug has been indicated
13prior to the time of issuance; the term does not mean a written
14prescription that is individually generated by machine or
15computer in the prescriber's office.
16    (mm) "Prescriber" means a physician licensed to practice
17medicine in all its branches, dentist, optometrist, podiatrist
18or veterinarian who issues a prescription, a physician
19assistant who issues a prescription for a controlled substance
20in accordance with Section 303.05, a written delegation, and a
21written supervision agreement required under Section 7.5 of the
22Physician Assistant Practice Act of 1987, or an advanced
23practice nurse with prescriptive authority delegated under
24Section 65-40 of the Nurse Practice Act and in accordance with
25Section 303.05, a written delegation, and a written
26collaborative agreement under Section 65-35 of the Nurse

 

 

SB1454 Engrossed- 22 -LRB098 09389 RPM 39530 b

1Practice Act.
2    (nn) "Prescription" means a written, facsimile, or oral
3order, or an electronic order that complies with applicable
4federal requirements, of a physician licensed to practice
5medicine in all its branches, dentist, podiatrist or
6veterinarian for any controlled substance, of an optometrist
7for a Schedule III, IV, or V controlled substance in accordance
8with Section 15.1 of the Illinois Optometric Practice Act of
91987, of a physician assistant for a controlled substance in
10accordance with Section 303.05, a written delegation, and a
11written supervision agreement required under Section 7.5 of the
12Physician Assistant Practice Act of 1987, or of an advanced
13practice nurse with prescriptive authority delegated under
14Section 65-40 of the Nurse Practice Act who issues a
15prescription for a controlled substance in accordance with
16Section 303.05, a written delegation, and a written
17collaborative agreement under Section 65-35 of the Nurse
18Practice Act when required by law.
19    (nn-5) "Prescription Information Library" (PIL) means an
20electronic library that contains reported controlled substance
21data.
22    (nn-10) "Prescription Monitoring Program" (PMP) means the
23entity that collects, tracks, and stores reported data on
24controlled substances and select drugs pursuant to Section 316.
25    (nn-11) "Prescription Monitoring Program Advisory
26Committee" (PMPAC) means a committee of voting members

 

 

SB1454 Engrossed- 23 -LRB098 09389 RPM 39530 b

1consisting of licensed healthcare providers representing all
2professions who are licensed to prescribe or dispense
3controlled substances. The Chairperson of the PMPAC may appoint
4non-licensed persons who are associated with professional
5organizations representing licensed healthcare providers.
6Non-licensed members shall serve as non-voting members. A
7majority of the PMPAC shall be licensed health care providers
8who are licensed to prescribe controlled substances. The
9Committee shall serve in a consultant context regarding
10longitudinal evaluations of compliance with evidence based
11clinical practice and the prescribing of controlled
12substances. The Committee shall make recommendations regarding
13scheduling of controlled substances and recommendations
14concerning continuing education designed at improving the
15health and safety of the citizens of Illinois regarding
16pharmacotherapies of controlled substances.
17    (oo) "Production" or "produce" means manufacture,
18planting, cultivating, growing, or harvesting of a controlled
19substance other than methamphetamine.
20    (pp) "Registrant" means every person who is required to
21register under Section 302 of this Act.
22    (qq) "Registry number" means the number assigned to each
23person authorized to handle controlled substances under the
24laws of the United States and of this State.
25    (qq-5) "Secretary" means, as the context requires, either
26the Secretary of the Department or the Secretary of the

 

 

SB1454 Engrossed- 24 -LRB098 09389 RPM 39530 b

1Department of Financial and Professional Regulation, and the
2Secretary's designated agents.
3    (rr) "State" includes the State of Illinois and any state,
4district, commonwealth, territory, insular possession thereof,
5and any area subject to the legal authority of the United
6States of America.
7    (rr-5) "Stimulant" means any drug that (i) causes an
8overall excitation of central nervous system functions, (ii)
9causes impaired consciousness and awareness, and (iii) can be
10habit-forming or lead to a substance abuse problem, including
11but not limited to amphetamines and their analogs,
12methylphenidate and its analogs, cocaine, and phencyclidine
13and its analogs.
14    (ss) "Ultimate user" means a person who lawfully possesses
15a controlled substance for his or her own use or for the use of
16a member of his or her household or for administering to an
17animal owned by him or her or by a member of his or her
18household.
19(Source: P.A. 96-189, eff. 8-10-09; 96-268, eff. 8-11-09;
2097-334, eff. 1-1-12.)
 
21    (720 ILCS 570/208.5 new)
22    Sec. 208.5. Dihydrocodeinone (Hydrocodone).
23    (a) Dihydrocodeinone (Hydrocodone) with one or more
24active, non-narcotic ingredients in regional therapeutic
25amounts is a Schedule III controlled substance, subject to the

 

 

SB1454 Engrossed- 25 -LRB098 09389 RPM 39530 b

1requirements for prescribing of Schedule III controlled
2substances with the exception that any prescription must be
3limited to no more than a 30-day supply with any continuation
4requiring a new prescription. Prescribers may issue multiple
5prescriptions (3 sequential 30-day supplies) for
6Dihydrocodeinone (Hydrocodone), authorizing up to a 90-day
7supply. Before authorizing a 90-day supply of Dihydrocodeinone
8(Hydrocodone), the prescriber must meet the following
9conditions:
10        (1) each separate prescription must be issued for a
11    legitimate medical purpose by an individual prescriber
12    acting in the usual course of professional practice; and
13        (2) the individual prescriber must provide written
14    instructions on each prescription (other than the first
15    prescription, if the prescribing physician intends for the
16    prescription to be filled immediately) indicating the
17    earliest date on which a pharmacy may fill that
18    prescription.
19    (b) Nothing in this Section shall be construed to affect
20hospitals, long-term care facilities, hospices, and other
21institutions addressed in Section 313.
 
22    (720 ILCS 570/316)
23    Sec. 316. Prescription monitoring program.
24    (a) The Department must provide for a prescription
25monitoring program for Schedule II, III, IV, and V controlled

 

 

SB1454 Engrossed- 26 -LRB098 09389 RPM 39530 b

1substances, the purpose of which is to develop a clinical tool
2to assist healthcare providers in preventing accidental
3overdoses or duplications of controlled substances to the
4patients they are treating. The program shall include that
5includes the following components and requirements:
6        (1) The dispenser must transmit to the central
7    repository, in a form and manner specified by the
8    Department, the following information:
9            (A) The recipient's name.
10            (B) The recipient's address.
11            (C) The national drug code number of the controlled
12        substance dispensed.
13            (D) The date the controlled substance is
14        dispensed.
15            (E) The quantity of the controlled substance
16        dispensed.
17            (F) The dispenser's United States Drug Enforcement
18        Administration registration number.
19            (G) The prescriber's United States Drug
20        Enforcement Administration registration number.
21            (H) The dates the controlled substance
22        prescription is filled.
23            (I) The payment type used to purchase the
24        controlled substance (i.e. Medicaid, cash, third party
25        insurance).
26            (J) The patient location code (i.e. home, nursing

 

 

SB1454 Engrossed- 27 -LRB098 09389 RPM 39530 b

1        home, outpatient, etc.) for the controlled substances
2        other than those filled at a retail pharmacy.
3            (K) Any additional information that may be
4        required by the department by administrative rule,
5        including but not limited to information required for
6        compliance with the criteria for electronic reporting
7        of the American Society for Automation and Pharmacy or
8        its successor.
9        (2) The information required to be transmitted under
10    this Section must be transmitted not more than 7 days after
11    the date on which a controlled substance is dispensed, or
12    at such other time as may be required by the Department by
13    administrative rule.
14        (3) A dispenser must transmit the information required
15    under this Section by:
16            (A) an electronic device compatible with the
17        receiving device of the central repository;
18            (B) a computer diskette;
19            (C) a magnetic tape; or
20            (D) a pharmacy universal claim form or Pharmacy
21        Inventory Control form;
22        (4) The Department may impose a civil fine of up to
23    $100 per day for willful failure to report controlled
24    substance dispensing to the Prescription Monitoring
25    Program. The fine shall be calculated on no more than the
26    number of days from the time the report was required to be

 

 

SB1454 Engrossed- 28 -LRB098 09389 RPM 39530 b

1    made until the time the problem was resolved, and shall be
2    payable to the Prescription Monitoring Program.
3    (b) The Department, by rule, may include in the monitoring
4program certain other select drugs that are not included in
5Schedule II, III, IV, or V. The prescription monitoring program
6does not apply to controlled substance prescriptions as
7exempted under Section 313.
8    (c) The collection of data on select drugs and scheduled
9substances by the Prescription Monitoring Program may be used
10as a tool for addressing oversight requirements of long-term
11care institutions as set forth by Public Act 96-1372. Long-term
12care pharmacies shall transmit patient medication profiles to
13the Prescription Monitoring Program monthly or more frequently
14as established by administrative rule.
15    (d) By January 1, 2018, all Electronic Health Records
16Systems should interface with the Prescription Monitoring
17Program application program interface to insure that all
18providers have access to specific patient records as they are
19treating the patient. No prescriber shall be fined or otherwise
20penalized if the electronic health records system he or she is
21using does not effectively interface with the Prescription
22Monitoring Program.
23(Source: P.A. 97-334, eff. 1-1-12.)
 
24    (720 ILCS 570/317.5 new)
25    Sec. 317.5. Access to the Prescription Monitoring Program

 

 

SB1454 Engrossed- 29 -LRB098 09389 RPM 39530 b

1Database.
2    (a) All licensed prescribers of controlled substances may
3register for individual access to the Prescription Monitoring
4Program, where the data is to be used in treating their
5patients.
6    (b) Those licensed prescribers who have registered to
7access the Prescription Monitoring Program may authorize a
8designee to consult the Prescription Monitoring Program on
9their behalf. The practitioner assumes all liability from that
10authorization. The Prescription Monitoring Program Advisory
11Committee shall draft rules with reasonable parameters
12concerning a practitioner's authority to authorize a designee.
13    (c) Any Electronic Medical Records System may apply for
14access to the Prescription Monitoring Program on behalf of
15their enrolled practitioners.
16    (d) A pharmacist-in-charge (PIC) or his or her designee
17(which may be permitted by administrative rules) may register
18for individual access to the Prescription Monitoring Program.
19    (e) Any Pharmacy Electronic Record System may apply for
20access to the Prescription Monitoring Program on behalf of
21their enrolled pharmacies to streamline access to patient
22specific data to address provision of pharmaceutical care.
23    (f) Prescribers, pharmacists, or persons acting on their
24behalf, in good faith, are immune from any recourse (civil or
25criminal liability, or professional discipline) arising from
26any false, incomplete or inaccurate information submitted to or

 

 

SB1454 Engrossed- 30 -LRB098 09389 RPM 39530 b

1reported to the Prescription Monitoring Program registry.
 
2    (720 ILCS 570/319)
3    Sec. 319. Rules. The Department must adopt rules under the
4Illinois Administrative Procedure Act to implement Sections
5316 through 321, including the following:
6        (1) Information collection and retrieval procedures
7    for the central repository, including the controlled
8    substances to be included in the program required under
9    Section 316 and Section 321 (now repealed).
10        (2) Design for the creation of the database required
11    under Section 317.
12        (3) Requirements for the development and installation
13    of on-line electronic access by the Department to
14    information collected by the central repository.
15        (4) The process for choosing members for the advisory
16    committee, the clinical consulting long term care advisory
17    committee, and the clinical outcomes research group under
18    the direction of the Prescription Monitoring Program
19    Clinical Director.
20(Source: P.A. 97-334, eff. 1-1-12.)
 
21    (720 ILCS 570/320)
22    Sec. 320. Advisory committee.
23    (a) The Secretary of the Department of Human Services must
24appoint an advisory committee to assist the Department in

 

 

SB1454 Engrossed- 31 -LRB098 09389 RPM 39530 b

1implementing the controlled substance prescription monitoring
2program created by Section 316 and former Section 321 of this
3Act. The Advisory Committee consists of prescribers and
4dispensers.
5    (b) The Secretary of the Department of Human Services or
6his or her designee must determine the number of members to
7serve on the advisory committee. The Chair of the Prescription
8Monitoring Program Advisory Committee and the other clinical
9consulting committees shall be the Prescription Monitoring
10Program Clinical Director Secretary must choose one of the
11members of the advisory committee to serve as chair of the
12committee.
13    (c) The advisory committee may appoint its other officers
14as it deems appropriate.
15    (d) The members of the advisory committee shall receive no
16compensation for their services as members of the advisory
17committee but may be reimbursed for their actual expenses
18incurred in serving on the advisory committee.
19    (e) The advisory committee shall:
20        (1) provide a uniform approach to reviewing this Act in
21    order to determine whether changes should be recommended to
22    the General Assembly.
23        (2) review current drug schedules in order to manage
24    changes to the administrative rules pertaining to the
25    utilization of this Act.
26(Source: P.A. 97-334, eff. 1-1-12.)